CWA
Clarus Wealth Advisors’s iShares Biotechnology ETF IBB Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-10,831
| Closed | -$1.28M | – | 91 |
|
|
2025
Q1 | $1.28M | Sell |
10,831
-552
| -5% | -$65.5K | 0.69% | 38 |
|
|
2024
Q4 | $1.53M | Buy |
11,383
+161
| +1% | +$21.6K | 0.76% | 39 |
|
|
2024
Q3 | $1.6M | Sell |
11,222
-121
| -1% | -$17.2K | 0.81% | 37 |
|
|
2024
Q2 | $1.59M | Buy |
11,343
+419
| +4% | +$58.9K | 0.85% | 32 |
|
|
2024
Q1 | $1.44M | Buy |
10,924
+529
| +5% | +$69.7K | 0.82% | 34 |
|
|
2023
Q4 | $1.4M | Buy |
+10,395
| New | +$1.4M | 0.83% | 33 |
|
|
2023
Q2 | $1.21M | Buy |
9,744
+1,047
| +12% | +$130K | 0.74% | 35 |
|
|
2023
Q1 | $1.14M | Buy |
+8,697
| New | +$1.14M | 0.72% | 35 |
|
|
2022
Q1 | – | Sell |
-8,046
| Closed | -$1.14M | – | 118 |
|
|
2021
Q4 | $1.14M | Buy |
8,046
+1,074
| +15% | +$152K | 0.66% | 34 |
|
|
2021
Q3 | $1.09M | Buy |
6,972
+442
| +7% | +$68.8K | 0.67% | 34 |
|
|
2021
Q2 | $1.06M | Buy |
6,530
+385
| +6% | +$62.6K | 0.66% | 34 |
|
|
2021
Q1 | $914K | Sell |
6,145
-155
| -2% | -$23.1K | 0.57% | 36 |
|
|
2020
Q4 | $995K | Buy |
6,300
+170
| +3% | +$26.8K | 0.66% | 32 |
|
|
2020
Q3 | $845K | Buy |
6,130
+57
| +0.9% | +$7.86K | 0.65% | 33 |
|
|
2020
Q2 | $851K | Sell |
6,073
-519
| -8% | -$72.7K | 0.72% | 31 |
|
|
2020
Q1 | $700K | Buy |
6,592
+347
| +6% | +$36.8K | 0.7% | 36 |
|
|
2019
Q4 | $756K | Buy |
+6,245
| New | +$756K | 0.5% | 52 |
|
|
2019
Q3 | – | Sell |
-1,368
| Closed | -$149K | – | 325 |
|
|
2019
Q2 | $149K | Sell |
1,368
-3,856
| -74% | -$420K | 0.11% | 143 |
|
|
2019
Q1 | $584K | Buy |
5,224
+4,984
| +2,077% | +$557K | 0.44% | 32 |
|
|
2018
Q4 | $23K | Sell |
240
-12,682
| -98% | -$1.22M | 0.04% | 380 |
|
|
2018
Q3 | $1.58M | Buy |
12,922
+526
| +4% | +$64.2K | 1.03% | 13 |
|
|
2018
Q2 | $1.32M | Hold |
12,396
| – | – | 1% | 12 |
|
|
2018
Q1 | $1.32M | Buy |
12,396
+4,094
| +49% | +$437K | 1.22% | 12 |
|
|
2017
Q4 | $886K | Buy |
+8,302
| New | +$886K | 0.85% | 19 |
|